The Diversity of the Endocrine System 42
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Laboratory Procedure Manual
Laboratory Procedure Manual Analyte: Thyroid Stimulating Hormone Matrix: Serum Method: Microparticle Enzyme Immunoassay (MEIA) Method No.: Revised: as performed by: Coulston Foundation Alamogordo, New Mexico Contact: Ms. Love Julian 1-505-434-1725 Important Information for Users Coulston periodically refines these laboratory methods. It is the responsibility of the user to contact the person listed on the title page of each write-up before using the analytical method to find out whether any changes have been made and what revisions, if any, have been incorporated. Thyroid Stimulating Hormone NHANES 2001–2002 Public Release Data Set Information This document details the Lab Protocol for NHANES 2001-2002 data. Two laboratories performed this testing during 2001-2002. In order to maintain confidentiality of the participants the quality control summary statistics and graphs were combined to mask the individual analysis dates from the two laboratories. Methods for both labs are included in this release. The method for Lab18 analyte is included in this file. The method for Lab40 is described in a separate file. A tabular list of the released analytes follows: Lab Number Analyte SAS Label lab18 LBXTSH Thyroid Stimulating Hormone Page 2 of 11 Thyroid Stimulating Hormone NHANES 2001-2002 1. Summary of Test Principle and Clinical Relevance IMx Ultrasensitive hTSH II is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of human thyroid stimulating hormone (hTSH) in serum or plasma on the IMx analyzer. The IMx Ultrasensitive hTSH II assay is based on the MEIA technology. The IMx Ultrasensitive hTSH II reagents and sample are added to the reaction cell in the following sequence: The probe/electrode assembly delivers the sample and anti-hTSH coated microparticles to the incubation well of the reaction cell. -
A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: the Effect on Keratinocyte Subpopulations
Acta Derm Venereol 2004; 84: 195–200 INVESTIGATIVE REPORT A Left/Right Comparison of Twice-Daily Calcipotriol Ointment and Calcitriol Ointment in Patients with Psoriasis: The Effect on Keratinocyte Subpopulations Mannon E.J. FRANSSEN, Gys J. DE JONGH, Piet E.J. VAN ERP and Peter C.M. VAN DE KERKHOF Department of Dermatology, University Medical Centre Nijmegen, The Netherlands Vitamin D3 analogues are a first-line treatment of Calcipotriol (Daivonex1,50mg/g ointment, Leo chronic plaque psoriasis, but so far, comparative clinical Pharmaceutical Products, Denmark) has been investi- studies on calcipotriol and calcitriol ointment are sparse, gated intensively during the last decade, and has proven and in particular no comparative studies are available on to be a valuable tool in the management of chronic cell biological effects of these compounds in vivo. Using plaque psoriasis. A review by Ashcroft et al. (1), based on flow cytometric assessment, we investigated whether these a large number of randomized controlled trials, showed compounds had different effects on the composition and that calcipotriol was at least as effective as potent DNA synthesis of epidermal cell populations responsible topical corticosteroids, 1a,-25-dihydroxycholecalciferol for the psoriatic phenotype. For 8 weeks, 20 patients with (calcitriol), short-contact dithranol, tacalcitol and coal psoriasis vulgaris were treated twice daily with calcipo- tar. Recently, Scott et al. (2) presented an overview of triol and calcitriol ointment in a left/right comparative studies on the use of calcipotriol ointment in the study. Before and after treatment, clinical assessment of management of psoriasis. They reconfirmed the super- target lesions was performed, together with flow cyto- ior efficacy of a twice-daily calcipotriol ointment metric analysis of epidermal subpopulations with respect regimen to the treatments as mentioned above, and to keratin (K) 10, K6, vimentin and DNA distribution. -
Endocrine System WS19
Endocrine System Human Physiology Unit 3 Endocrine System • Various glands located throughout the body • Some organs may also have endocrine functions • Endocrine glands/organs synthesize and release hormones • Hormones travel in plasma to target cells Functions of the Endocrine System • Differentiation of nervous and reproductive system during fetal development • Regulation of growth and development • Regulation of the reproductive system • Maintains homeostasis • Responds to changes from resting state Mechanisms of Hormone Regulation • Hormones have different rates and rhythms of secretion • Hormones are regulated by feedback systems to maintain homeostasis • Receptors for hormones are only on specific effector cells • Excretion of hormones vary for steroid hormones and peptide hormones Regulation of Hormone Secretion • Release of hormones occurs in response to • A change from resting conditions • Maintaining a regulated level of hormones or substances • Hormone release is regulated by • Chemical factors (glucose, calcium) • Endocrine factors (tropic hormones, HPA) HPA = Hypothalamic-Pituitary Axis • Neural controls (sympathetic activation) Hormone Feedback Systems Negative feedback maintains hormone concentrations within physiological ranges • Negative feedback • Feedback to one level Loss of • Long-loop Negative Feedback feedback • Feedback to two levels control often leads to • Hypothalamus-Pituitary-Gland Axis pathology Negative Feedback Short-Loop Negative Feedback Long-Loop Negative Feedback Hormone Transport Peptide/Protein Hormones -
The Role of Reproductive Hormones in Epithelial Ovarian Carcinogenesis
H Gharwan et al. Hormones and epithelial 22:6 R339–R363 Review ovarian cancer The role of reproductive hormones in epithelial ovarian carcinogenesis Helen Gharwan1, Kristen P Bunch2,3 and Christina M Annunziata2 1National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, 12N226, Bethesda, Correspondence Maryland 20892-1906, USA should be addressed 2Women’s Malignancies Branch, National Cancer Institute, National Institutes of Health, Center for Cancer Research, to H Gharwan Bethesda, Maryland, USA Email 3Department of Gynecologic Oncology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA [email protected] Abstract Epithelial ovarian cancer comprises w85% of all ovarian cancer cases. Despite acceptance Key Words regarding the influence of reproductive hormones on ovarian cancer risk and considerable " ovarian cancer advances in the understanding of epithelial ovarian carcinogenesis on a molecular level, " hormone action complete understanding of the biologic processes underlying malignant transformation of " reproductive ovarian surface epithelium is lacking. Various hypotheses have been proposed over the past " immune several decades to explain the etiology of the disease. The role of reproductive hormones in " endocrine epithelial ovarian carcinogenesis remains a key topic of research. Primary questions in the field of ovarian cancer biology center on its developmental cell of origin, the positive and negative effects of each class of hormones on ovarian cancer initiation and progression, and the role of the immune system in the ovarian cancer microenvironment. The development of the female reproductive tract is dictated by the hormonal milieu during embryogenesis. Endocrine-Related Cancer Intensive research efforts have revealed that ovarian cancer is a heterogenous disease that may develop from multiple extra-ovarian tissues, including both Mu¨ llerian (fallopian tubes, endometrium) and non-Mu¨ llerian structures (gastrointestinal tissue), contributing to its heterogeneity and distinct histologic subtypes. -
Using T3 for Treatment of Hypothyroidism - What the Evidence Say?
Journal of Endocrinology and Thyroid Research ISSN: 2573-2188 Review Article J Endocrinol Thyroid Res Volume 2 Issue 2- June 2017 Copyright © All rights are reserved by Vismay Naik, DOI: 10.19080/JETR.2017.02.555584 Using T3 For Treatment of Hypothyroidism - What the Evidence Say? Vismay Naik* Ashirvad Heart and Diabetes Centre, India Submission: March 01, 2017; Published: June 27, 2017 *Corresponding author: Vismay Naik, MD, MRCP (London), Ashirvad Heart and Diabetes Centre, Botad, Gujarat, India, Email: Introduction Hypothyroidism is due to the primary disease of the thyroid Treatment Strategies of Hypothyroidism or secondary to hypothalamic- pituitary disease [1]. Primary The objectives of management of hypothyroidism are to hypothyroidism is the most common endocrine disorder reverse clinical progression, correct metabolic abnormalities, throughout the world. Traditionally we have been using [3] and reduction of goiter size in patients with autoimmune levothyroxine in the treatment of hypothyroidism. However, there Hashimoto’s thyroiditis [4]. This can be achieved by 3 different have been reports of persisting symptoms of hypothyroidism strategies: in 5-10% of levothyroxine treated hypothyroid patients a. Standard treatment with a daily dose levothyroxine (T4) in order to reach an age adjusted TSH target [5]. The with normal serum thyrotrophin (TSH) [2]. Physiologically dose has to be titrated periodically [3]. levothyronine is the active form, so treating the patient with the active form has been considered optimum treatment. This study b. Triiodothyronine (T3) monotherapy is the biological is aimed at reviewing the literature on using T3 in treatment of hypothyroidism either alone or in combination with T4. By the its short half-life [6] end of this study we hope to answer the question, if the use of T3 active form. -
A Clinical Update on Vitamin D Deficiency and Secondary
References 1. Mehrotra R, Kermah D, Budoff M, et al. Hypovitaminosis D in chronic 17. Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 32. Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of High 38. Kramer H, Berns JS, Choi MJ, et al. 25-Hydroxyvitamin D testing and kidney disease. Clin J Am Soc Nephrol. 2008;3:1144-1151. 25-hydroxyvitamin D targets for chronic kidney disease management vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin supplementation in CKD: an NKF-KDOQI controversies report. Am J may be too low. J Nephrol. 2016;29:63-70. D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD Kidney Dis. 2014;64:499-509. 2. Hollick MF. Vitamin D: importance in the prevention of cancers, type 1 with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial. diabetes, heart disease, and osteoporosis. Am J Clin Nutr 18. OPKO. OPKO diagnostics point-of-care system. Available at: http:// J Med Assoc Thai. 2015;98:643-648. 39. Jetter A, Egli A, Dawson-Hughes B, et al. Pharmacokinetics of oral 2004;79:362-371. www.opko.com/products/point-of-care-diagnostics/. Accessed vitamin D(3) and calcifediol. Bone. 2014;59:14-19. September 2 2015. 33. Kovesdy CP, Lu JL, Malakauskas SM, et al. Paricalcitol versus 3. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 40. Petkovich M, Melnick J, White J, et al. Modified-release oral calcifediol of vitamin D status and cancer incidence and mortality in men. -
Endocrine Paraneoplastic Syndromes: a Review
Endocrinology & Metabolism International Journal Review Article Open Access Endocrine paraneoplastic syndromes: a review Abstract Volume 1 Issue 1 - 2015 Paraneoplastic endocrine syndromes result from ectopic production of hormones by Hala Ahmadieh,1 Asma Arabi2 different tumors. Hypercalcemia of malignancy is the most common, mostly caused by 1Division of Endocrinology, American University of Beirut, ectopic parathyroid hormone related peptide (PTHrP) production which increases bone Lebanon resorption. Other causes include the rare ectopic parathyroid hormone (PTH) production, 2Department of Internal Medicine, American University of ectopic production of 1, 25-(OH)2 vitamin D by the tumor and its adjacent macrophages and Beirut-Medical Center, Lebanon bone metastasis which by itself in addition to the local production of PTHrP at the level of the bone lead to bone resorption and thus hypercalcemia. Treatment includes extracellular Correspondence: Asma Arabi, Department of Internal fluid volume repletion, bisphosphonates or denosumab and calcitonin. Ectopic Cushing’s Medicine, Division of Endocrinology, American University of syndrome caused by ectopic ACTH production results in hypokalemia, proximal muscle Beirut-Medical Center, Po Box 11-0236, Riad El-Solh, Beirut, weakness, easy bruisability, hypertension, diabetes and psychiatric abnormalities including Lebanon, Email depression and mood disorders. Different diagnostic measures help to differentiate Cushing’s disease from ectopic Cushing’s syndrome. Treatment includes surgical resection Received: October 26, 2014 | Published: January 02, 2015 of tumor and medical therapy to suppress excess cortisol production. Ectopic secretion of ADH has been associated with different tumor types. The best treatment options include removal of the underlying tumor, chemotherapy, or radiotherapy in addition to free water restriction, demeclocycline and vaptans. -
TGF-Β Signaling Proteins and CYP24A1 May Serve As Surrogate
1437 Original Article TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types Ana Paucarmayta1, Hannah Taitz1, Yovanni Casablanca1,2,3, Gustavo C. Rodriguez4, G. Larry Maxwell2,3,5, Kathleen M. Darcy2,3,6, Viqar Syed1,3,7 1Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA; 2Gynecologic Cancer Center of Excellence, 3John P. Murtha Cancer Center, Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center, Bethesda, MD, USA; 4Division of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Evanston, IL, USA; 5Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, VA, USA; 6Inova Schar Cancer Institute, Inova Center for Personalized Health, Falls Church, VA, USA; 7Department of Molecular and Cell Biology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA Contributions: (I) Conception and design: KM Darcy, GL Maxwell, V Syed; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: A Paucarmayta, H Taitz, V Syed; (V) Data analysis and interpretation: A Paucarmayta, H Taitz, KM Darcy, V Syed; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Viqar Syed. John P. Murtha Cancer Center, Department of Obstetrics and Gynecology, Department of Molecular and Cell Biology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Room# A-3080, Bethesda, MD, USA. Email: [email protected]. Background: Strategies are needed to coordinately block drivers and induce suppressors of cancer to reduce incidence and improve outcomes for individuals with inherited or acquired risk. -
Vitamin D3 Constrains Estrogen's Effects and Influences Mammary
www.nature.com/scientificreports OPEN Vitamin D3 constrains estrogen’s efects and infuences mammary epithelial organization in 3D Received: 16 January 2019 Accepted: 18 April 2019 cultures Published: xx xx xxxx Nafs Hasan 1, Carlos Sonnenschein1,2 & Ana M. Soto 1,2 Vitamin D3 (vitD3) and its active metabolite, calcitriol (1,25-(OH)2D3), afect multiple tissue types by interacting with the vitamin D receptor (VDR). Although vitD3 defciency has been correlated with increased incidence of breast cancer and less favorable outcomes, randomized clinical trials have yet to provide conclusive evidence on the efcacy of vitD3 in preventing or treating breast cancer. Additionally, experimental studies are needed to assess the biological plausibility of these outcomes. The mammary gland of VDR KO mice shows a forid phenotype revealing alterations of developmental processes that are largely regulated by mammotropic hormones. However, most research conducted on vitD3’s efects used 2D cell cultures and supra-physiological doses of vitD3, conditions that spare the microenvironment in which morphogenesis takes place. We investigated the role of vitD3 in mammary epithelial morphogenesis using two 3D culture models. VitD3 interfered with estrogen’s actions on T47D human breast cancer cells in 3D diferently at diferent doses, and recapitulated what is observed in vivo. Also, vitD3 can act autonomously and afected the organization of estrogen-insensitive MCF10A cells in 3D collagen matrix by infuencing collagen fber organization. Thus, vitD3 modulates mammary tissue organization independent of its efects on cell proliferation. Breast cancer remains a major cause of mortality among women worldwide. Epidemiological studies have shown that key stages during breast development are particularly susceptible to the efects of carcinogens. -
A Randomized, Masked Study of Triiodothyronine Plus Thyroxine Administration in Preterm Infants Less Than 28 Weeks of Gestational Age: Hormonal and Clinical Effects
0031-3998/04/5502-0248 PEDIATRIC RESEARCH Vol. 55, No. 2, 2004 Copyright © 2004 International Pediatric Research Foundation, Inc. Printed in U.S.A. A Randomized, Masked Study of Triiodothyronine Plus Thyroxine Administration in Preterm Infants Less Than 28 Weeks of Gestational Age: Hormonal and Clinical Effects PAOLO G. VALERIO, ALEID G. VAN WASSENAER, JAN J.M. DE VIJLDER, AND JOKE H. KOK Department of Neonatology [P.G.V., A.G.v.W., J.H.K.] and Laboratory of Pediatric Endocrinology [J.J.M.d.V.], Academic Medical Center, Emma Children’s Hospital, 1105 AZ Amsterdam, The Netherlands ABSTRACT A randomized, placebo-controlled, masked study was con- effect on cortisol levels. We did not find any effects of T3 or of ducted of the responses of thyroid parameters, cortisol, and the T4 administration on the cardiovascular system. A single injec- cardiovascular system to a single dose of triiodothyronine (T3) tion of T3 (0.5 g/kg) given 22–26 h after birth only leads to a 24 h after birth, followed by a daily dose of thyroxine (T4) during 2-d increase of T3 levels and does not have effects on the Ͻ 6 wk to infants 28 wk gestational age. Thirty-one infants were cardiovascular system. This study does not support the use of T3 assigned to three groups: 1) group A: T3 24 h after birth plus according to our regimen in preterm infants. (Pediatr Res 55: daily T4 during 6 wk; 2) group B: placebo T3 and T4 during 6 wk; 248–253, 2004) and 3) group C: placebo T3 and placebo T4.T4, free T4,T3, free T3, reverse T3, thyroid-stimulating hormone, and cortisol were measured in cord blood and on days 1, 3, 7, 14, 21, 42, and 56. -
Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial
ANTICANCER RESEARCH 37 : 6575-6581 (2017) doi:10.21873/anticanres.12114 Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro TEA KUITTINEN 1, PÄIVI ROVIO 1, SYNNÖVE STAFF 1,2 , TIINA LUUKKAALA 3,4 , ANNE KALLIONIEMI 5,6 , SEIJA GRÉNMAN 7,8 , MARITA LAURILA 9 and JOHANNA MÄENPÄÄ 1,10 1Department of Obstetrics and Gynaecology, Tampere University Hospital, Tampere, Finland; 2Laboratory of Cancer Biology, BioMediTech Institute, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland; 3Research and Innovation Centre, Tampere University Hospital, Tampere, Finland; 4Health Sciences, Faculty of Social Sciences, University of Tampere, Tampere, Finland; 5BioMediTech Institute and Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland; 6Fimlab Ltd, Tampere University Hospital, Tampere, Finland; 7Department of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland; 8University of Turku, Turku, Finland; 9Department of Pathology, Fimlab Ltd, Tampere University Hospital, Tampere, Finland; 10 Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland Abstract. Background/Aim: Endometrial cancer cells are combination of these compounds. The corresponding numbers known to be sensitive to carboplatin and paclitaxel. in UT-EC-3 were 70%, 33% and 65%, respectively. 1,25-D3 Further more , vitamin D (1,25-D3) has been reported to inhibit suppressed cell growth 88% with paclitaxel, 63% with endometrial cancer cell growth both as a single agent and carboplatin and 87% with their combination in the UT-EC-1 combined with carboplatin. However, there are no studies cell line. Conclusion: In both cell lines, single-agent paclitaxel comparing the effect of paclitaxel and carboplatin as single was as effective as the combination of the compounds and agents vs. -
Endocrine Abnormalities of the Horse Scott M. Austin, DVM, MS, DACVIM
Endocrine abnormalities of the horse Scott M. Austin, DVM, MS, DACVIM Clinical Associate Professor of Equine Medicine Department of Veterinary Clinical Medicine University of Illinois Summary: Endocrine abnormalities occur frequently in the horse. The clinical presentation of common conditions may have significant overlap resulting in diagnostic confusion. It is important to arrive at an accurate diagnosis, as the successful therapy for endocrine abnormalities is contingent upon the correct diagnosis. Hypothyroidism: Much of the confusion around hypothyroidism is a result of the erroneous association of this condition with obesity, laminitis and infertility. Research that is more recent indicates that hypothyroidism is actually quite rare. In the limited case reports of documented hypothyroidism in horses, the primary clinical signs are lethargy, exercise intolerance, and poor quality haircoat. In horses that had thyroids removed, neither weight gain nor laminitis were seen. Diagnosis: The hypothalamus regulates the production of thyroid hormones through the actions of thyrotropin-releasing hormone (TRH), which stimulates the anterior pituitary gland to release thyroid- stimulating hormone (TSH). TSH then regulates the synthesis and release of thyroid hormones by the thyroid gland. In response to TSH stimulus, triiodothyronine (T3) and thyroxin (T4) are released from the thyroid gland into the bloodstream bound to either thyroglobulins or other proteins such as albumin. T4 has minimal activity and is essentially a prohormone. T3 is the primary active form of the hormone, and only unbound T3 can enter a cell and activate the vital functions attributable to this hormone. The common measurement of total T3 and T4 often provides erroneous values and does not provide a clear picture of thyroid function.